On March 2, 2023, the Human Research Ethics Committee (HREC) of Australia granted permission to Accro Bioscience Inc. for clinical testing of its RIPK2 inhibitor AC-101.

Receptor interacting protein kinase 2 (RIP2) is a member of the receptor interacting serine/threonine protein kinase family. Dysregulation of NOD/RIPK2 dependent signaling pathways is associated with human diseases, such as inflammatory bowel disease (IBD) and sarcoidosis.

AC-101 is a novel oral small-molecule inhibitor of RIPK2 with high activity, selectivity, and safety window. The preclinical studies have shown that AC-101 effectively inhibits the release of the NOD-RIPK2 dependent inflammatory factors, and has significant protective effects in IBD models. AC-101 is the leading RIPK2 asset worldwide.

Accro Bioscience Inc. owns all intellectual property rights and global interests of AC-101.